Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | VNN1 | O95497 | 1/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 12/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 12/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 12/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 12/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.35 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.34 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.33 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 1/20 | 0.33 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.33 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.33 |
| ▸ | CDK2 | P24941 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29725003 | 0.88 | PDE4B (0.42) | KCNH2VNN1HDAC3HDAC1HDAC2 | |
| SCHEMBL12288024 | 0.88 | PDE4B (0.42) | KCNH2VNN1HDAC3HDAC1HDAC2 | |
| SCHEMBL14990526 | 0.86 | KCNH2 (0.45) | KCNH2PDE4BMKNK1MKNK2RORC | |
| SCHEMBL12294322 | 0.85 | KCNH2 (0.51) | KCNH2VNN1PDE4BFGFR4MKNK1 | |
| SCHEMBL2565298 | 0.84 | KCNH2 (0.43) | KCNH2PDE4BMKNK1MKNK2RORC | |
| SCHEMBL12294255 | 0.84 | HDAC6 (0.50) | VNN1HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL29724839 | 0.82 | HDAC3 (0.49) | KCNH2VNN1HDAC3HDAC1HDAC2 | |
| SCHEMBL14936917 | 0.82 | HDAC3 (0.49) | KCNH2VNN1HDAC3HDAC1HDAC2 | |
| SCHEMBL12288592 | 0.81 | ROCK2 (0.40) | KCNH2VNN1HDAC3HDAC1HDAC2 | |
| SCHEMBL29724793 | 0.81 | ROCK2 (0.40) | KCNH2VNN1HDAC3HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2560488-B1 | CERTAIN AMINO-PYRIDINES AND AMINO-TRIAZINES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | CYTOKINETICS INC (US) | 2015-10-28 | — | — | EP | claimed |
| US-9133123-B2 | Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use | CYTOKINETICS, INC. (US) | 2015-09-15 | — | — | US | claimed |
| US-9994528-B2 | Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use | CYTOKINETICS, INC. (US) | 2018-06-12 | — | — | US | disclosed |
| US-9994528-B2 | Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use | CYTOKINETICS, INC. (US) | 2018-06-12 | — | — | US | disclosed |
| US-9994528-B2 | Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use | CYTOKINETICS, INC. (US) | 2018-06-12 | — | — | US | disclosed |
| US-20160200717-A1 | CERTAIN AMINO-PYRIDINES AND AMINO-TRIAZINES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | CYTOKINETICS INC (US) | 2016-07-14 | — | — | US | disclosed |
| US-20160200717-A1 | CERTAIN AMINO-PYRIDINES AND AMINO-TRIAZINES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | CYTOKINETICS INC (US) | 2016-07-14 | — | — | US | disclosed |
| US-20160200717-A1 | CERTAIN AMINO-PYRIDINES AND AMINO-TRIAZINES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | CYTOKINETICS INC (US) | 2016-07-14 | — | — | US | disclosed |
| EP-2560488-B1 | CERTAIN AMINO-PYRIDINES AND AMINO-TRIAZINES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | CYTOKINETICS INC (US) | 2015-10-28 | — | — | EP | disclosed |
| EP-2560488-B1 | CERTAIN AMINO-PYRIDINES AND AMINO-TRIAZINES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | CYTOKINETICS INC (US) | 2015-10-28 | — | — | EP | disclosed |
| US-9133123-B2 | Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use | CYTOKINETICS, INC. (US) | 2015-09-15 | — | — | US | disclosed |
| US-9133123-B2 | Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use | CYTOKINETICS, INC. (US) | 2015-09-15 | — | — | US | disclosed |
| US-9133123-B2 | Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use | CYTOKINETICS, INC. (US) | 2015-09-15 | — | — | US | disclosed |
| US-20130150368-A1 | CERTAIN AMINO-PYRIDINES AND AMINO-TRIAZINES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | CYTOKINETICS, INC. (US) | 2013-06-13 | — | — | US | disclosed |
| US-20130150368-A1 | CERTAIN AMINO-PYRIDINES AND AMINO-TRIAZINES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | CYTOKINETICS, INC. (US) | 2013-06-13 | — | — | US | disclosed |
| US-20130150368-A1 | CERTAIN AMINO-PYRIDINES AND AMINO-TRIAZINES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | CYTOKINETICS, INC. (US) | 2013-06-13 | — | — | US | disclosed |
| WO-2011133920-A1 | CERTAIN AMINO-PYRIDINES AND AMINO-TRIAZINES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | CYTOKINETICS, INC. (US) | 2011-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160200717-A1 | CERTAIN AMINO-PYRIDINES AND AMINO-TRIAZINES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | SLC7A1, PRMT5, H1-5 | KCNH2 463/4885VNN1 4156/4885HDAC3 602/4885 |
| US-20130150368-A1 | CERTAIN AMINO-PYRIDINES AND AMINO-TRIAZINES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | SLC7A1, PRMT5, H1-5 | KCNH2 463/4885VNN1 4156/4885HDAC3 602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.